Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
BioAtla
(NASDAQ:BCAB)
Intraday
$2.25
-0.10
[-4.26%]
After-Hours
$2.25
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.25
-0.10
[-4.26%]
At close: Apr 25
$2.25
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for BioAtla Stock (NASDAQ:BCAB)
BioAtla Stock (NASDAQ: BCAB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 28, 2024
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Benzinga Newsdesk
-
Mar 28, 2024, 10:34AM
Wednesday, March 27, 2024
BioAtla shares are trading higher after the company reported Q4 financial results.
Benzinga Newsdesk
-
Mar 27, 2024, 12:24PM
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $7
Benzinga Newsdesk
-
Mar 27, 2024, 6:26AM
Tuesday, March 26, 2024
BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
Benzinga Newsdesk
-
Mar 26, 2024, 5:35PM
BioAtla: Q4 Earnings Insights
Benzinga Insights
-
Mar 26, 2024, 5:35PM
Earnings Scheduled For March 26, 2024
Benzinga Insights
-
Mar 26, 2024, 4:47AM
Monday, March 25, 2024
Preview: BioAtla's Earnings
Benzinga Insights
-
Mar 25, 2024, 12:00PM
Wednesday, December 20, 2023
Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor
-
Dec 20, 2023, 8:31AM
Monday, December 18, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Dec 18, 2023, 4:31PM
Wednesday, December 13, 2023
BioAtla Hosting Virtual R&D Day To Highlight BA3071 CAB-CTLA-4 Phase 1 Data In Multiple Solid Tumor Types
Benzinga Newsdesk
-
Dec 13, 2023, 8:23AM
Tuesday, December 05, 2023
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Benzinga Newsdesk
-
Dec 5, 2023, 9:17AM
BioAtla Presented Phase 2 Clinical Trial Data At The IASLC 2023 North America Conference On Lung Cancer And Virtual KOL Event
Benzinga Newsdesk
-
Dec 5, 2023, 8:07AM
Monday, December 04, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Dec 4, 2023, 12:31PM
Wednesday, November 08, 2023
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $10
Benzinga Newsdesk
-
Nov 8, 2023, 8:11AM
Tuesday, November 07, 2023
BioAtla Q3 2023 Cash, Cash Equivalents $141.3M
Benzinga Newsdesk
-
Nov 7, 2023, 4:04PM
BioAtla Sees H2 2025 Cash Balance $141.3M
Benzinga Newsdesk
-
Nov 7, 2023, 4:04PM
Earnings Scheduled For November 7, 2023
Benzinga Insights
-
Nov 7, 2023, 6:34AM
Tuesday, October 10, 2023
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
Benzinga Newsdesk
-
Oct 10, 2023, 7:35AM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Monday, September 25, 2023
Analyst Ratings for BioAtla
Benzinga Insights
-
Sep 25, 2023, 12:00PM
JP Morgan Maintains Overweight on BioAtla, Lowers Price Target to $14
Benzinga Newsdesk
-
Sep 25, 2023, 9:36AM
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 15, 2023, 11:52AM
Wednesday, August 02, 2023
JP Morgan Maintains Overweight on BioAtla, Lowers Price Target to $17
Benzinga Newsdesk
-
Aug 2, 2023, 1:36PM
JMP Securities Reiterates Market Outperform on BioAtla, Maintains $12 Price Target
Benzinga Newsdesk
-
Aug 2, 2023, 9:40AM
The Latest Analyst Ratings for BioAtla
Benzinga Insights
-
Aug 2, 2023, 9:00AM
EF Hutton Reiterates Buy on BioAtla, Maintains $25 Price Target
Benzinga Newsdesk
-
Aug 2, 2023, 7:16AM
HC Wainwright & Co. Reiterates Buy on BioAtla, Maintains $17 Price Target
Benzinga Newsdesk
-
Aug 2, 2023, 6:20AM
Tuesday, August 01, 2023
BioAtla Q2 EPS $(0.75) Misses $(0.62) Estimate
Benzinga Newsdesk
-
Aug 1, 2023, 5:28PM
Earnings Scheduled For August 1, 2023
Benzinga Insights
-
Aug 1, 2023, 4:06AM
Monday, June 26, 2023
BioAtla Added To Membership Of U.S. Small-Cap Russell 2000 Index
Happy Mohamed
-
Jun 26, 2023, 8:14AM
Monday, May 15, 2023
Where BioAtla Stands With Analysts
Benzinga Insights
-
May 15, 2023, 9:02AM
JMP Securities Reiterates Outperform on BioAtla, Maintains $12 Price Target
Benzinga Newsdesk
-
May 15, 2023, 8:47AM
HC Wainwright & Co. Reiterates Buy on BioAtla, Maintains $17 Price Target
Benzinga Newsdesk
-
May 15, 2023, 6:48AM
Friday, May 12, 2023
EF Hutton Reiterates Buy on BioAtla, Maintains $25 Price Target
Benzinga Newsdesk
-
May 12, 2023, 10:23AM
BioAlta shares are trading higher after the company reported Q1 financial results.
Benzinga Newsdesk
-
May 12, 2023, 10:13AM
Thursday, May 11, 2023
BioAtla Q1 EPS $(0.58) Beats $(0.63) Estimate
Benzinga Newsdesk
-
May 11, 2023, 6:02PM
Earnings Scheduled For May 11, 2023
Benzinga Insights
-
May 11, 2023, 9:58AM
Monday, April 17, 2023
EF Hutton Maintains Buy on BioAtla, Maintains $25 Price Target
Benzinga Newsdesk
-
Apr 17, 2023, 6:06PM
Monday, April 03, 2023
JP Morgan Maintains Overweight on BioAtla, Lowers Price Target to $19
Benzinga Newsdesk
-
Apr 3, 2023, 8:24AM
Friday, March 31, 2023
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin
-
Mar 31, 2023, 7:10AM
Tuesday, March 28, 2023
BTIG Maintains Buy on BioAtla, Lowers Price Target to $13
Benzinga Newsdesk
-
Mar 28, 2023, 6:09AM
Monday, March 27, 2023
JMP Securities Maintains Outperform on BioAtla, Lowers Price Target to $12
Benzinga Newsdesk
-
Mar 27, 2023, 6:36AM
Friday, March 24, 2023
Expert Ratings for BioAtla
Benzinga Insights
-
Mar 24, 2023, 5:00PM
Credit Suisse Reiterates Neutral on BioAtla, Maintains $8 Price Target
Benzinga Newsdesk
-
Mar 24, 2023, 8:01AM
EF Hutton Reiterates Buy on BioAtla, Maintains $25 Price Target
Benzinga Newsdesk
-
Mar 24, 2023, 7:10AM
HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $17
Benzinga Newsdesk
-
Mar 24, 2023, 6:18AM
Thursday, March 23, 2023
BioAtla Cash Balance Of $215.5M At Year-End 2022; Q4 Net Loss Of $(27.5M) Vs $(23.4M) YoY
Michael Horton
-
Mar 23, 2023, 4:09PM
Earnings Scheduled For March 23, 2023
Benzinga Insights
-
Mar 23, 2023, 8:10AM
Wednesday, March 22, 2023
Earnings Outlook For BioAtla
Benzinga Insights
-
Mar 22, 2023, 12:01PM
Thursday, February 23, 2023
BioAtla Announces FDA Clearance Of Investigational New Drug Application For BA3182
Benzinga Newsdesk
-
Feb 23, 2023, 8:05AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch